Previous 10 | Next 10 |
BioMarin Pharmaceutical (BMRN): Q2 GAAP EPS of $0.07 beats by $0.18.Revenue of $501.69M (+16.8% Y/Y) beats by $53.17M.2021 Guidance: Revenue: $1.79B - 1.88B from $1.75B - 1.85B vs. consensus of $1.82B; Vimizim: $580M - 620M from $570M - 610M; Kuvan: $260M - 290M; Naglazyme: $375M - 405M from ...
BioMarin Announces Second Quarter 2021 Financial Results and Corporate Updates - Total Revenues Grew 17% in the Second Quarter 2021 Compared to Second Quarter 2020 - Raising Full-year 2021 Financial Guidance - Marketing Authorization Application (MAA) for Valoctocogene R...
BioMarin Announces Oral Presentation at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress with 5 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec in Adults with Severe Hemophilia A, Demonstrating Continued, Durable Clinical B...
Michael Vi/iStock Editorial via Getty Images New data demonstrates that BioMarin Pharmaceutical's ([[BMRN]] -0.9%) gene therapy valoctocogene roxaparvovec, was superior to Factor VIII prophylaxis in a phase 3 trial based on efficacy endpoints. Patients on valoctocogene rox...
BioMarin Announces Oral Presentation of Positive One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress Largest Gene Therapy S...
European Medicines Agency Validates BioMarin's Marketing Authorization Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A Potential 1st Gene Therapy in Europe for Treatment of Hemophilia A CHMP Opinion Anticipated in 1H 2022 PR Newswire SAN...
BioMarin to Host Second Quarter 2021 Financial Results Conference Call and Webcast on Wednesday, July 28 at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , July 14, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bien...
Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...
BioMarin Announces 12 Presentations at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress Findings to be Presented from Ongoing Studies of Valoctocogene Roxaparvovec Represent Largest and Longest Development Program for any Gene Therapy in Hemop...
BioMarin Resubmits Marketing Authorization Application (MAA) to European Medicines Agency for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A Valoctocogene Roxaparvovec MAA Granted Request for Accelerated Assessment PR Newswire SAN RAFAEL, Calif. , June...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease PR Newswire Now Approved for Children of All Ages with CLN2 Batten Disease, Regardless of Whether They Yet Show Symptoms SAN RAFAEL, C...
BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander ...
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...